Skip to main content
. 2015 Nov 25;27(4):699–705. doi: 10.1093/annonc/mdv545

Figure 1.

Figure 1.

Radiographic progression-free survival (A) and overall survival (B) in post-docetaxel metastatic castration-resistant prostate cancer patients treated with abiraterone acetate (AA) plus prednisone (P) or placebo plus P as a function of Gleason score (<8 and ≥8) at initial diagnosis. AA, abiraterone acetate; CI, confidence interval; HR, hazard ratio; P, prednisone.